News Article | April 17, 2017
With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are...
News Article | April 18, 2017
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics Corporation (Ambry) is calling on psychiatrists, psychologists and behavioral specialists to encourage their patients with autism, along with their family members, to sign up for a new study conducted through Ambry’s data sharing program, AmbryShare. With this program, Ambry is taking a step towards discovering possible associations between genes and autism, so clinicians can provide their patients with targeted treatments and therapies much earlier in life. “What’s unique about AmbryShare’s approach is that we collect genetic information from clinics and families from all over the world to answer questions that can’t be answered with just a handful of patients,” said Brigette Tippin Davis, PhD, Ambry’s Director of Emerging Genetic Medicine. “The great thing about Ambry partnerships is that we are building connections between research institutions and empowering them to develop new approaches to treating patients with autism based on genetic profiles.” So far, dozens of behavioral clinics and other medical offices have contributed to AmbryShare studies by encouraging participation from their patients. Ambry strives to enroll more than 10,000 patients from clinics nationally and internationally. “Genetic testing would allow us to personalize treatment from a genetic profile and optimize it together with our rich behavioral data,” said Dennis Dixon, PhD, Chief Strategy Officer at Center for Autism and Related Disorders (CARD). “I really value working with Ambry, knowing this data will have an impact on treatment for our patients and then will still be available for other researchers to access to answer additional research questions. As we each put more samples in, it increases the overall likelihood that we’re going to find something that really makes a difference.” One in 64 children in the United States is diagnosed with an autism spectrum disorder (ASD), which can impact social interaction, communication and behavior. Genetic testing can help identify an underlying cause in up to 40% of autism spectrum disorders. Some genetic causes include chromosome microdeletions/microduplications, fragile X syndrome, Angelman syndrome, and tuberous sclerosis. New gene discovery can allow clinicians to determine their patient’s course of treatment and the gene-disease relationship associated with their individual case of autism. Through the recruitment of a massive cohort, more data will be collected to discover more genes, develop medical management plans and enact preventive strategies. “The scientists need the data to be out there,” said Charles Dunlop, Ambry’s President and Chairman. “We need to know what these diseases are actually doing, what causes them, what gene mutations are associated with them so we can move forward as an industry and move onto the next phase where there is no disease of any kind. A phase where pharmaceutical researchers know exactly what to do, or exactly what problems they’re trying to solve at a minutiae level—that’s when the cures come.” In 2016, Mayo Clinic and University of Utah collaborated with Ambry on a new research study of more than 60,000 patients to help refine breast cancer risk estimates from predisposition genes that are either previously lacking data or have limited data. The study, “Breast cancer risks associated with mutations in cancer predisposition genes identified by clinical genetic testing of 60,000 breast cancer patients” represented the largest genetic study of women with hereditary breast cancer. The large amount of data was able to provide researchers with new information about genes that contributed to breast cancer risk. Ambry wants to provide researchers with the same capabilities for autism. Since 2001, Ambry has been dedicated to scientific research to help empower the scientific community and refine clinician management guidelines so patients may receive tailored medical management. AmbryShare’s initial launch in 2016 provided scientific researchers and clinicians with the largest open, de-identified database of hereditary breast and ovarian cancer cohorts with the goal of achieving a greater understanding of human disease. For more information and to enroll in the AmbryShare autism study, visit the AmbryShare portal here. Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com. About the Center for Autism and Related Disorders (CARD) CARD treats individuals of all ages who are diagnosed with autism spectrum disorder (ASD) at treatment centers around the globe. CARD was founded in 1990 by leading autism expert and clinical psychologist Doreen Granpeesheh, PhD, BCBA-D. CARD treats individuals with ASD using the principles of applied behavior analysis (ABA), which is empirically proven to be the most effective method for treating individuals with ASD and recommended by the American Academy of Pediatrics and the US Surgeon General. CARD employs a dedicated team of over 3,000 individuals across the nation and internationally. For more information, visit www.centerforautism.com or call (855) 345-2273.
News Article | April 26, 2017
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Progeny Genetics LLC (Progeny), a leading risk modeling pedigree software for clinicians, announced today that Jamie L’Heureux, MS, CGC has been appointed to the role of Chief Executive Officer. For 20 years, Progeny has assisted healthcare providers with patient screening, risk analysis, order processing, clinical review, and letter generation. Ms. L’Heureux brings over 12 years of experience in both research and clinical genetics as a Board Certified genetic counselor. She received her Master’s degree in Medical Genetics from the University of Cincinnati’s Genetic Counseling Training Program and began her career at the University of Iowa as a Research Coordinator for several international research projects. Ms. L’Heureux’s strong background in software development includes implementing new laboratory information management systems and designing patient-facing Family History Questionnaires. For the past three years, Ms. L’Heureux served as Software Product Manager at Progeny, and was integral to development of Progeny’s letter generation feature and integrated risk models. “I am excited to be able to use my past experience as a Progeny user, both in the research and clinical genetic counseling settings, to help build upon the strong foundation that Progeny already has established, and make it even more user-friendly for our healthcare provider customers and their patients,” said Ms. L’Heureux. “We have some exciting improvements coming up that are focused on saving clinicians’ time and simplifying their workflow.” As a prominent member of the Progeny leadership team, Ms. L’Heureux helps guide the future of the company by leveraging her extensive experience as a genetic counselor. In addition, her software development knowledge provides a solid foundation for Ms. L’Heureux to harness the needs of Progeny’s healthcare provider clientele. Progeny’s software is available in over 2,400 unique sites in 80 countries worldwide. Progeny has played a prominent role in advancing science by bringing family history to the forefront of genetic healthcare, with the intention that the information provided to healthcare providers will assist them with early detection and intervention to patients with genetic predispositions. Progeny became a subsidiary of Ambry Genetics (Ambry), a genetic testing company based in Aliso Viejo, California, in April 2015. Progeny’s software helps healthcare providers analyze hereditary family history data so clinicians can effectively identify genetic risk factors in patients and their families. For more information about Progeny’s services and support, visit here. Progeny is a subsidiary of Ambry Genetics, providing customizable family history, pedigree, sample, and genetic data management software solutions to healthcare providers worldwide. Using Progeny’s sophisticated technology, healthcare providers can collect family history from patients, review and edit pedigrees, run integrated risk models, order and review genetic testing, and integrate into the electronic medical record, allowing healthcare providers to embrace personalized healthcare like never before. For more information about Progeny, visit www.progenygenetics.com. Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com.
News Article | April 17, 2017
A recent survey of over 2,000 women newly diagnosed with breast cancer found that half of those who undergo bilateral mastectomy after genetic testing don't actually have mutations known to confer increased risk of additional cancers, according to a study by researchers at the Stanford University School of Medicine and four other U.S. medical centers. Instead the women had what are known as variants of uncertain significance, or VUS, that are often eventually found to be harmless. A bilateral mastectomy is a surgical procedure in which both of a woman's breasts are removed after a diagnosis of cancer in one breast. The finding highlights the need for genetic counselors to help both patients and physicians better understand the results of genetic testing intended to determine a woman's risk for cancer recurrence or for developing a separate cancer in her ovaries or unaffected breast. "Our findings suggest a limited understanding among physicians and patients of the meaning of genetic testing results," said Allison Kurian, MD, associate professor of medicine and of health research and policy at Stanford. "Clinical practice guidelines state that variants of uncertain significance should not be considered to confer high cancer risk, and that patients with these variants should be counseled similarly to a patient whose genetic test is normal. However, many of the physicians surveyed in our study stated that they manage these patients in the same way as they do patients with mutations known to increase a woman's risk." Only about half of the surveyed women who received genetic testing ever discussed their test results with a genetic counselor, and between one-quarter and one-half of the surveyed breast cancer surgeons indicated they treat women with VUS no differently than women with known cancer-associated mutations, the researchers found. Furthermore, some women undergo surgery prior to receiving genetic testing or seeing the results. Kurian is the lead author of the study, which will be published online April 12 in the Journal of Clinical Oncology. University of Michigan researchers Reshma Jagsi, MD, DPhil, and Steven Katz, MD, MPH, share senior authorship. The findings come on the heels of a February study by many of the same researchers showing that physicians often fail to recommend genetic testing for breast cancer patients at high risk for mutations in the BRCA1 or BRCA2 genes, which are strongly associated with ovarian and other cancers. In this study, the researchers asked 2,502 women newly diagnosed with breast cancer whether they had received genetic testing, and if so, whether the testing and any discussion of results occurred before or after breast surgery. They found that of the 666 women who had received testing, 59 percent were considered to have a high risk of a dangerous mutation in a cancer-associated gene. About one-quarter of these women had genetic testing only after surgery -- meaning critical decisions were made about their care before information about their mutation status was available. Delays in testing were particularly pronounced in women who lacked private health insurance. The researchers then polled the surgeons who treated the women in the survey. They found that, when compared with doctors who had treated 51 or more newly diagnosed breast cancer patients during the previous year, doctors who had treated fewer than 21 breast cancer patients were: less confident in discussing the results of genetic testing with patients, more likely to order the genetic test without referring women to a genetic counselor, less likely to delay surgery in order to have test results available for surgical decision-making and more likely to manage a patient with variants of uncertain significance in the same way they would manage patients with proven high-risk mutations in cancer-associated genes. "Our findings suggest that we are not maximizing the benefit of genetic testing for our patients with breast cancer because of barriers related to timeliness of testing and lack of expertise necessary to incorporate results into treatment decisions," said Katz, who is a professor of medicine and of health management and policy at the University of Michigan. Although genetic testing has become more common and less costly, it's also become more confusing. The advent of multiplex gene panels that simultaneously test for mutations or variations in many different genes can render results that are difficult to interpret without the help of a trained genetic counselor. Uncertainties as to the meaning of test results may lead less-experienced surgeons to recommend aggressive treatment in the form of bilateral mastectomies, or cause women to opt for what they may feel is the safest option to manage their cancer. Conversely, high-risk women who do carry dangerous mutations need this information to make informed decisions about their health care choices. "The gaps identified in this study are striking," said Jagsi, professor and deputy chair of radiation oncology at the University of Michigan. "It is critical to ensure that patients at high risk for known cancer-associated mutations are fully informed of the potential benefits of genetic testing, and counseled accurately about the meaning of test results." "We're learning that clinicians' knowledge of breast cancer genetics can be highly variable," said Kurian, who is a member of the Stanford Cancer Institute. "It's important for women at high risk of carrying a dangerous mutation to see someone with expertise in cancer genetics when planning their care. Unfortunately, in many cases genetic counselors may not be optimally integrated into the care of newly diagnosed cancer patients, making it difficult to rapidly triage these patients. Our study highlights the urgent need for improved patient access to cancer genetics experts, particularly genetic counselors, and for educating physicians about the appropriate use of genetic testing and interpretation of test results." Researchers from the University of Southern California, Emory University and the Memorial Sloan-Kettering Cancer Center also contributed to the study. The study was supported by the National Institutes of Health (grant P01CA163233), the California Department of Public Health and the Centers for Disease Control and Prevention. Kurian has received research funding from Invitae, Myriad Genetics, Ambry Genetics, GenDx and Genomic Health. Stanford's departments of Medicine and of Health Research and Policy also supported the work. The Stanford University School of Medicine consistently ranks among the nation's top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med. . The medical school is part of Stanford Medicine, which includes Stanford Health Care and Stanford Children's Health. For information about all three, please visit http://med. .
News Article | July 7, 2017
TOKYO & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Konica Minolta, Inc. (Konica Minolta) (TOKYO: 4902) (ISIN: JP3300600008) and Ambry Genetics Corporation (Ambry) today announced the signing of a definitive agreement for a subsidiary of Konica Minolta to acquire Ambry. The transaction is partially funded by Innovation Network Corporation of Japan (INCJ). $800 million will be paid upon closure, and there will be an additional payment of up to $200 million based on certain financial metrics over the next two years, valuing the acquisition up to a total of $1.0 billion. Founded in 1999, Ambry is a privately held healthcare company in the U.S., led by founder, President and Chairman Charles L.M. Dunlop and CEO Dr. Aaron Elliott. Ambry has the world’s most comprehensive suite of genetic testing solutions for inherited and non-inherited diseases as well as for numerous clinical specialties, including oncology, cardiology, pulmonology, neurology, and general genetics. They are recognized as a leader in diagnostic solutions for hereditary conditions in the United States, by having performed more than one million genetic tests and identified more than 45,000 mutations in at least 500 different genes. Ambry is known as a pioneer and thought leader in genetic testing being the first laboratory in the world to offer such tests as hereditary cancer panels and clinical exome sequencing. Konica Minolta views the addition of Ambry as the first stepping-stone to create an exciting new medical platform aimed at fulfilling the potential of precision medicine – an emerging approach to healthcare where genetic or molecular analysis is used to match patients with the most appropriate treatment for their specific disease. Precision medicine aims to improve a patients’ quality of life and save the healthcare system money by eliminating unnecessary and ineffective treatments. Konica Minolta plans to bring Ambry’s capabilities first to Japan, and then to Europe. “ This acquisition is the first in a series of strategic initiatives to secure a leading position for Konica Minolta in precision medicine”, said Shoei Yamana, President and CEO of Konica Minolta. “ The future of medicine is patient-focused. Together with Ambry, we will have the most comprehensive set of diagnostic technologies for mapping an individual’s genetic and biochemical makeup, as well as the capabilities to translate that knowledge into information the medical community can use to discover, prevent, and cost-effectively treat diseases. This will not only serve as the future foundation for our healthcare business, but will pave the way for a fundamental shift in the way medicine is practiced globally.” The acquisition of Ambry and the advancement of precision medicine marks a strategic and important shift for Konica Minolta’s healthcare business. Leveraging its long history of innovation in materials science, nanofabrication, optics, and imaging, Konica Minolta has developed a comprehensive range of technologies and services in the healthcare field spanning digital X-ray diagnostic imaging systems, diagnostic ultrasound systems, and ICT service platforms for medical institutions. Ambry’s genetic testing capabilities complement Konica Minolta’s advanced imaging technology to create the most comprehensive range of healthcare diagnostics for use by pharmaceutical companies, healthcare providers, payers, and consumers. In 2015, Konica Minolta pioneered advanced immunostaining technology – High-Sensitivity Tissue Testing (HSTT)1 – that uses fluorescent nanoparticles to detect and quantify the proteins that drive disease states and offers far greater precision and accuracy than conventional immunostaining techniques. With initial applications in oncology, the proprietary technology can determine the exact cellular location and amount of specific proteins that manifest in cells, offering an early-stage, highly precise diagnosis and insights into a patient’s disease that can inform research and a clinicians’ treatment plan. “ We’re excited by this opportunity to combine both our companies’ technologies to unlock new opportunities for precision medicine,” said Charles Dunlop, President and Chairman of Ambry Genetics. “ As a part of Konica Minolta, we will have the resources, technology, and scale to advance biomedical research and enable the matching of more patients in more countries with specialized medicines that target the underlying cause of their illness.” Konica Minolta’s HSTT technology will be further enhanced by Ambry’s genetics-based screening techniques, which enable clinicians to analyze both tumor and normal tissue to diagnose hereditary cancer, while also providing guidance regarding drug eligibility and response. Ambry recently launched a combined genetic test for both inherited and acquired mutations in DNA mismatch repair genes to indicate appropriate treatment options for cancer patients who may benefit from PD-1/PD-L1 immunotherapy. PD-1 and PD-L1 checkpoint inhibitors help the patient's immune system recognize attack and destroy PD-L1-positive cancer cells that would otherwise evade detection by the immune system. “ The combination of these bioinformatics capabilities, alongside Konica Minolta’s HSTT technology, will create new opportunities for drug discovery and clinical trials not currently available,” said Kiyotaka Fujii, Senior Executive Officer, President, Global Healthcare, Konica Minolta. “ Konica Minolta will look to accelerate innovations by drawing on the strengths of both companies. In addition to introducing Ambry’s genetic-testing capabilities to the Japan market, we will look to develop new bio-imaging and proteomic services and solutions to benefit doctors, patients, and pharmaceutical companies.” Transaction Overview Under the terms of the agreement, Konica Minolta via Konica Minolta Healthcare Americas, Inc., (MHUS), a wholly owned subsidiary of Konica Minolta, and INCJ, will make an upfront, all-cash payment of $800 million to Ambry. MHUS will invest 60% and INCJ will account for the remaining 40%. In addition, Ambry shareholders will receive up to $200 million in incremental consideration based on certain financial metrics over the next two years, valuing the acquisition up to a total of $1.0 billion. The transaction is expected to close in the third quarter of fiscal year 2017, subject to customary regulatory approvals. Ambry would thereafter become a consolidated subsidiary of Konica Minolta, continuing to operate under the Ambry name and headquartered in Aliso Viejo, California. GCA Corporation acted as financial advisor to Konica Minolta and Baker McKenzie acted as legal advisor for this transaction. Intrepid Investment Bankers acted as financial advisor to Ambry and Jones Day acted as legal advisor. ABOUT KONICA MINOLTA Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, we create products and digital solutions for the betterment of business and society—today and for generations to come. Across our Business Technologies, Healthcare, and Industrial-facing businesses, we aspire to be an Integral Value Provider that applies the full range of our company’s expertise to offer comprehensive solutions to our customer’s most pressing problems, work with our partners to ensure our solutions are sustainable, anticipate and address tomorrow’s issues, and tailor each solution to meet the unique and specific needs of our valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for our customers, and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/ About Ambry Genetics Since 1999, Ambry’s mission has remained focused on understanding disease so cures can come faster. Today, Ambry remains unwavering in its commitment to being tough, innovative, committed to quality and, most of all, focused to do what is right for patient care. For more information on Ambry’s full suite of genetic testing, visit http://www.ambrygen.com About INCJ Innovation Network Corporation of Japan (INCJ), a unique public-private partnership aimed at promoting innovation and enhancing the value of businesses in Japan, was launched in July 2009. For more information please see: http://www.incj.co.jp/english/ 1 A portion of the research on HSTT was commissioned under a project by the New Energy and Industrial Technology Development Organization (NEDO), Japan.
News Article | December 7, 2016
ROCHESTER, Minn. -- Inherited pathogenic variants in protein coding genes BARD1 and RAD51D increase a woman's likelihood of developing breast cancer, according to research conducted at Mayo Clinic and presented today at the 2016 San Antonio Breast Cancer Symposium. Pathogenic variants are changes in DNA that have a negative impact on a gene's ability to function properly. "The BARD1 and RAD51D genes, have been included in clinical testing panels to determine breast cancer risk," says Fergus Couch, Ph.D., a geneticist at Mayo Clinic and lead author of the study. "However, the genes were identified as 'breast cancer' genes through very small studies, so there has never been strong evidence indicating that they are important in driving breast cancer risk." Dr. Couch and his colleagues studied data from 65,000 women with breast cancer to obtain risk estimates associated with 21 cancer predisposition genes from testing panels. They found that pathogenic variants in certain genes, such as BARD1 and RAD51D, caused moderately increased risks of breast cancer. These researchers also confirmed the involvement of the ATM, CHEK2 and PALB2 genes in breast cancer. They also found that the RAD50 and MRE11A genes did not increase risks of breast cancer. "Our findings are important, because genes that do not increase risk of breast cancer can now be ignored and potentially removed from clinical testing panels," Dr. Couch says. "I am hopeful this work will lead to much better interpretation of results from clinical, hereditary [and] genetic testing." Dr. Couch's research included data supplied by Ambry Genetics. Dr. Couch has no relevant financial disclosures. As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call the Clinical Trial Referral Office at 1-855-776-0015 (toll-free). Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www. or http://newsnetwork. .
News Article | November 23, 2016
Cancer Diagnostics Market by Methods (Tumor Biomarker Tests, Imaging, Endoscopy, and Biopsy) for Blood Cancer, Breast Cancer, Colorectal Cancer (CRC), Lung Cancer, Other: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2014 – 2020 The report covers forecast and analysis for the cancer diagnostics market on a global and regional level. The study provides historic data of 2014 along with a forecast from 2015 to 2020 based revenue (USD Billion). The study includes drivers and restraints for the cancer diagnostics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the cancer diagnostics market on a global level. In order to give the users of this report a comprehensive view on the cancer diagnostics. To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the cancer diagnostics market has also been included. The study encompasses a market attractiveness analysis, wherein methods segments and application segments are benchmarked based on their market size, growth rate and general attractiveness. The study provides a decisive view on the cancer diagnostics market by segmenting the market based on methods of diagnostics, applications and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2014 to 2020. Based on methods the market is segmented into tumor biomarker tests, imaging, endoscopy, and biopsy. Key application market covered under this study includes blood cancer, breast cancer, colorectal cancer (CRC), kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, and prostate cancer. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa with its further bifurcation into major countries including U.S. Germany, France, UK, China, Japan, India and Brazil. This segmentation includes demand for cancer diagnostics based on individual applications in all the regions and countries. The report also includes detailed profiles of end players such as Abbott Laboratories, Inc., Ambry Genetics, AstraZeneca plc, bioMeriux SA, Eli Lilly and Company, Genoptix, Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and Pfizer, Inc. The detailed description of players includes parameters such as company overview, financial overview, business and recent developments of the company. This report segments the global cancer diagnostics market as follows:
News Article | February 21, 2017
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics (Ambry) has created an online portal to enable more patients and families to participate in research through the AmbryShare program. With this simplified portal, Ambry has streamlined the research consent process to make cohort recruitment easier for clinicians at the time of sample collection for clinical testing. Patients now have the flexibility to e-consent from home, or a mobile device during their office visits. An individual can also enroll themselves and submit a sample to the program independently, whether or not their clinician orders a clinical test at Ambry. The new e-consent portal is one more example of the company’s mission to use AmbryShare to remove the red-tape that has been slowing down scientific progress. The data-sharing program is currently focused on the genomics of autism and prostate cancer, and Ambry is actively seeking research partners for those initiatives. “We've created a simple way for patients to participate in crowd-sourced research,” said Brigette Tippin Davis, PhD, Ambry’s Director of Emerging Genetic Medicine. “If your family is impacted by disease, we are empowering you to make a real difference. AmbryShare freely enables researchers worldwide to put your de-identified genomic DNA to work to find treatments, keeping your privacy protected at the same time.” Since March 2016, Ambry has provided researchers with de-identified aggregated data from whole exome sequencing on a large cohort of affected patients with the intention of aiding and accelerating scientific research at no cost to the public. This data will ultimately help clinicians create more tailored treatments through enhanced understanding of human disease. For more information and to enroll in AmbryShare, visit the AmbryShare portal here. Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit www.ambrygen.com.
News Article | March 8, 2016
Ambry Genetics is expected to announce on Tuesday that it will put information from 10,000 customers into a publicly available database.
News Article | March 10, 2016
Ambry Genetics, a prominent DNA-testing firm located in Orange County, CA, unveiled a new databank on Tuesday containing the aggregated genetic information of 10,000 patients with hereditary breast and ovarian cancer. The free initiative named AmbryShare is open to the public, but the information is anonymized. It was engineered to help support President Obama’s Precision Medicine program.